RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be parti
Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to

New Strong Sell Stocks for March 24th

06:30am, Monday, 24'th Mar 2025
AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025.
RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Oper
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASD
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASD
On Thursday, Amphastar Pharmaceuticals Inc. AMPH reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.

Amphastar: Earnings Miss, Margins Drop

09:56am, Friday, 28'th Feb 2025
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications Willia
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.92 per share, missing the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.88 per share a year ago.
Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphast
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE